Fundies. English
Segment disclosures
Company overview23ANDME HOLDING CO
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
19 dimension combinations 161 retained observations 20 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Customer B · Sales Revenue Net · Customer Concentration Risk · Consumer And Research Services
Major Customers · Concentration Risk By Benchmark · Concentration Risk By Type · Statement Business Segments
Source dimensions
srt:MajorCustomersAxis=me:CustomerBMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:ConsumerAndResearchServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 39917000 | USD | 20210708 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 23768000 | USD | 20210708 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 6533000 | USD | 20210708 | Open filing evidence |
Customer B · Sales Revenue Net · Customer Concentration Risk · Therapeutics
Major Customers · Concentration Risk By Benchmark · Concentration Risk By Type · Statement Business Segments
Source dimensions
srt:MajorCustomersAxis=me:CustomerBMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:TherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-04-01 – 2020-03-31 | 2981000 | USD | 20210708 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 2981000 | USD | 20210708 | Open filing evidence |
Customer C · Sales Revenue Net · Customer Concentration Risk · Consumer And Research Services
Major Customers · Concentration Risk By Benchmark · Concentration Risk By Type · Statement Business Segments
Source dimensions
srt:MajorCustomersAxis=me:CustomerCMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:ConsumerAndResearchServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 51786000 | USD | 20210708 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 76087000 | USD | 20210708 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 107318000 | USD | 20210708 | Open filing evidence |
Customer E · Sales Revenue Net · Customer Concentration Risk · Therapeutics
Major Customers · Concentration Risk By Benchmark · Concentration Risk By Type · Statement Business Segments
Source dimensions
srt:MajorCustomersAxis=me:CustomerEMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:TherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2020-04-01 – 2021-03-31 | 54000 | USD | 20210708 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 2575000 | USD | 20210708 | Open filing evidence |
Consumer And Research Services · Sales Revenue Net · Customer Concentration Risk · Customer B
Product Or Service · Concentration Risk By Benchmark · Concentration Risk By Type · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2024-03-31 | 11753000 | USD | 20240530 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 47448000 | USD | 20240530 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 46064000 | USD | 20240530 | Open filing evidence |
Consumer And Research Services · Sales Revenue Net · Customer C · Customer Concentration Risk
Product Or Service · Concentration Risk By Benchmark · Statement Business Segments · Concentration Risk By Type
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2024-03-31 | 48325000 | USD | 20240530 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 65721000 | USD | 20240530 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 53875000 | USD | 20240530 | Open filing evidence |
Consumer And Research Services · Customer Concentration Risk · Sales Revenue Net · Customer B
Product Or Service · Concentration Risk By Type · Concentration Risk By Benchmark · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-10-01 – 2023-12-31 | 0 | USD | 20240207 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 11753000 | USD | 20240207 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 13068000 | USD | 20240207 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 36258000 | USD | 20240207 | Open filing evidence |
Consumer And Research Services · Customer Concentration Risk · Customer C · Sales Revenue Net
Product Or Service · Concentration Risk By Type · Statement Business Segments · Concentration Risk By Benchmark
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-10-01 – 2023-12-31 | 8681000 | USD | 20240207 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 31432000 | USD | 20240207 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 14680000 | USD | 20240207 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 41365000 | USD | 20240207 | Open filing evidence |
Consumer And Research Services · Customer B
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 14925000 | USD | 20221107 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 23190000 | USD | 20221107 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 8246000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 46064000 | USD | 20220527 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 8069000 | USD | 20220211 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 29281000 | USD | 20220211 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 10002000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 21212000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 11209000 | USD | 20220809 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 39917000 | USD | 20220527 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 8554000 | USD | 20220211 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 30221000 | USD | 20220211 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 9840000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 21667000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 11827000 | USD | 20210813 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 23768000 | USD | 20220527 | Open filing evidence |
Consumer And Research Services · Customer C
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-04-01 – 2021-06-30 | 8512000 | USD | 20210813 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 5847000 | USD | 20210813 | Open filing evidence |
Therapeutics · Customer B
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:TherapeuticsMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2019-04-01 – 2020-03-31 | 2981000 | USD | 20220527 | Open filing evidence |
Therapeutics · Customer E
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=me:TherapeuticsMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerEMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2021-10-01 – 2021-12-31 | 0 | USD | 20220211 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 0 | USD | 20220211 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20211110 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 0 | USD | 20211110 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210813 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 54000 | USD | 20220527 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 0 | USD | 20220211 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 48000 | USD | 20220211 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 48000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 48000 | USD | 20210813 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 2575000 | USD | 20220527 | Open filing evidence |
Sales Revenue Net · Consumer And Research Services · Customer Concentration Risk · Customer B
Concentration Risk By Benchmark · Product Or Service · Concentration Risk By Type · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-04-01 – 2023-09-30 | 11753000 | USD | 20231108 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 10670000 | USD | 20230808 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 47448000 | USD | 20230525 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 13068000 | USD | 20230208 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 36258000 | USD | 20230208 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 14925000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 23190000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 8246000 | USD | 20230808 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 46064000 | USD | 20230525 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 8069000 | USD | 20230208 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 29281000 | USD | 20230208 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 39917000 | USD | 20230525 | Open filing evidence |
Customer Concentration Risk · Consumer And Research Services · Sales Revenue Net · Customer B
Concentration Risk By Type · Product Or Service · Concentration Risk By Benchmark · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerBMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-04-01 – 2024-06-30 | 1000 | USD | 20240808 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 11753000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 10670000 | USD | 20240808 | Open filing evidence |
Customer Concentration Risk · Consumer And Research Services · Sales Revenue Net · Customer C
Concentration Risk By Type · Product Or Service · Concentration Risk By Benchmark · Statement Business Segments
Source dimensions
us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember;srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 11586000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 19163000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 7577000 | USD | 20240808 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 13040000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 22751000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 9711000 | USD | 20240808 | Open filing evidence |
Consumer And Research Services
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=me:ConsumerAndResearchServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 44071000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 84485000 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 40414000 | USD | 20240808 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 219638000 | USD | 20240530 | Open filing evidence |
| 2023-10-01 – 2023-12-31 | 44747000 | USD | 20240207 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 155610000 | USD | 20240207 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 49999000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 110863000 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 60864000 | USD | 20240808 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 299489000 | USD | 20240530 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 66940000 | USD | 20240207 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 207112000 | USD | 20240207 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 75659000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 140172000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 64513000 | USD | 20230808 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 271893000 | USD | 20240530 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 56891000 | USD | 20230208 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 171334000 | USD | 20230208 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 55204000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 114443000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 59239000 | USD | 20220809 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 243866000 | USD | 20230525 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 55477000 | USD | 20220211 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 155290000 | USD | 20220211 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 51804000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 99813000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 48009000 | USD | 20210813 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 299907000 | USD | 20220527 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 437919000 | USD | 20210708 | Open filing evidence |
Customer C · Consumer And Research Services
Statement Business Segments · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember;srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 17057000 | USD | 20221107 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 26684000 | USD | 20221107 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 9628000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 53875000 | USD | 20220527 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 9676000 | USD | 20220211 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 33123000 | USD | 20220211 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 14935000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 23447000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 8512000 | USD | 20220809 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 51786000 | USD | 20220527 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 17451000 | USD | 20220211 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 31965000 | USD | 20220211 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 6840000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 13064000 | USD | 20211110 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 76087000 | USD | 20220527 | Open filing evidence |
Customer C · Sales Revenue Net · Consumer And Research Services · Customer Concentration Risk
Statement Business Segments · Concentration Risk By Benchmark · Product Or Service · Concentration Risk By Type
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=me:CustomerCMember;us-gaap:ConcentrationRiskByBenchmarkAxis=us-gaap:SalesRevenueNetMember;srt:ProductOrServiceAxis=me:ConsumerAndResearchServicesMember;us-gaap:ConcentrationRiskByTypeAxis=us-gaap:CustomerConcentrationRiskMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2023-07-01 – 2023-09-30 | 13040000 | USD | 20231108 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 22751000 | USD | 20231108 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 9711000 | USD | 20230808 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 65721000 | USD | 20230525 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 14680000 | USD | 20230208 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 41365000 | USD | 20230208 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 17057000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 26684000 | USD | 20231108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 9628000 | USD | 20230808 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 53875000 | USD | 20230525 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 9676000 | USD | 20230208 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 33123000 | USD | 20230208 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 51786000 | USD | 20230525 | Open filing evidence |
Therapeutics
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=me:TherapeuticsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2024-07-01 – 2024-09-30 | 0 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-09-30 | 0 | USD | 20241112 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 0 | USD | 20240808 | Open filing evidence |
| 2023-04-01 – 2024-03-31 | 0 | USD | 20240530 | Open filing evidence |
| 2023-10-01 – 2023-12-31 | 0 | USD | 20240207 | Open filing evidence |
| 2023-04-01 – 2023-12-31 | 0 | USD | 20240207 | Open filing evidence |
| 2023-07-01 – 2023-09-30 | 0 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-09-30 | 0 | USD | 20241112 | Open filing evidence |
| 2023-04-01 – 2023-06-30 | 0 | USD | 20240808 | Open filing evidence |
| 2022-04-01 – 2023-03-31 | 0 | USD | 20240530 | Open filing evidence |
| 2022-10-01 – 2022-12-31 | 0 Restated | USD | 20240207 | Open filing evidence |
| 2022-04-01 – 2022-12-31 | 0 Restated | USD | 20240207 | Open filing evidence |
| 2022-07-01 – 2022-09-30 | 75659000 | USD | 20221107 | Open filing evidence |
| 2022-04-01 – 2022-09-30 | 140172000 | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2022-03-31 | 0 | USD | 20240530 | Open filing evidence |
| 2021-10-01 – 2021-12-31 | 56891000 Restated | USD | 20230208 | Open filing evidence |
| 2021-04-01 – 2021-12-31 | 171334000 Restated | USD | 20230208 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 55204000 Restated | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-09-30 | 114443000 Restated | USD | 20221107 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20210813 | Open filing evidence |
| 2020-04-01 – 2021-03-31 | 54000 | USD | 20230525 | Open filing evidence |
| 2020-10-01 – 2020-12-31 | 0 | USD | 20220211 | Open filing evidence |
| 2020-04-01 – 2020-12-31 | 48000 | USD | 20220211 | Open filing evidence |
| 2020-07-01 – 2020-09-30 | 0 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-09-30 | 48000 | USD | 20211110 | Open filing evidence |
| 2020-04-01 – 2020-06-30 | 48000 | USD | 20210813 | Open filing evidence |
| 2019-04-01 – 2020-03-31 | 5556000 | USD | 20220527 | Open filing evidence |
| 2018-04-01 – 2019-03-31 | 2981000 | USD | 20210708 | Open filing evidence |